![](/img/cover-not-exists.png)
223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Forner, S, Sim, V R, Glendenning, J L, Burcombe, RVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy270.218
Date:
October, 2018
File:
PDF, 78 KB
2018